Back issues overview

LIVE 21 focuses on advancing immunology through innovative science, especially new drug approaches like covalent inhibitors.  It highlights collaboration across research, development, and patient communities to bring transformative therapies to patients.
The issue emphasizes improving outcomes with safer, more effective treatments and addressing previously “undruggable” diseases.

This issue of Live explores how innovation, research, and collaboration are transforming cardiovascular care worldwide. It highlights advances such as mini-heart models, precision medicine, and AI-driven health insights. A strong focus is placed on patient stories, prevention, and the need for better access and awareness.

The Institute of Molecular and Clinical Ophthalmology Basel (IOB) is pioneering revolutionary treatments for vision impairment through cutting-edge gene therapy, optogenetics, and mitochondrial research. Bridging academia and industry, the IOB has rapidly evolved into a global leader in ophthalmic translational research. Its collaborative model aims to significantly improve treatments for blindness and other eye conditions, transforming the future of ophthalmology.

In Travels in Medicine, our new Pavillon-focused issue of live magazine, we examine the achievements of the Pavillon's first two years, give you an update on the latest events and talk to some of the driving forces behind this institution that has been attracting huge crowds since 2022. We also take our readers on a journey to the places where healthcare is most needed and where medicine feels like an adventure.

Access to healthcare is a global challenge, not just limited to low- and middle-income countries. In the US city of Baltimore, Novartis is working with the Global Coalition on Aging to develop new models to help Black Americans improve their heart health. In addition to the Black Church, urban farmers and chefs are also part of this unique holistic effort that unites healthcare professionals with dedicated caregivers.

Cardiovascular disease remains the leading cause of death worldwide. Novartis is not only developing innovative medicines but also helping healthcare systems around the world to change the situation on the ground. In this issue of live, you can read about one such collaboration with a Japanese telemedicine company that combines home care with digital tools, among many others.